BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22404716)

  • 21. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
    González-Barón M; Ordóñez A; Franquesa R; Constenla M; Montalar J; Gili F; Camps C; Sancho JF; Pérez-Cachot P
    Cancer; 2002 Dec; 95(11):2408-13. PubMed ID: 12436449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.
    Bolger AP; Bartlett FR; Penston HS; O'Leary J; Pollock N; Kaprielian R; Chapman CM
    J Am Coll Cardiol; 2006 Sep; 48(6):1225-7. PubMed ID: 16979010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
    Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
    Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study.
    Portolés J; López-Gómez JM; Aljama P
    Nephrol Dial Transplant; 2007 Feb; 22(2):500-7. PubMed ID: 17023492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pre-transplant anemic condition is independent of long-term outcome in living-related kidney transplantation.
    Song T; Wang L; He S; Fu L; Huang Z; Wei Q; Lin T
    Ren Fail; 2014 Jun; 36(5):673-7. PubMed ID: 24512314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anemia and erythrocytosis after kidney transplantation: a 5-year graft function and survival analysis.
    Kolonko A; Pinocy-Mańdok J; Kocierz M; Kujawa-Szewieczek A; Chudek J; Malyszko J; Malyszko JS; Myśliwiec M; Wiecek A
    Transplant Proc; 2009 Oct; 41(8):3046-51. PubMed ID: 19857673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
    Ludwig H; Aapro M; Bokemeyer C; Macdonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
    Eur J Cancer; 2009 Jun; 45(9):1603-15. PubMed ID: 19278851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The epidemiology of hemoglobin levels in patients with type 2 diabetes.
    Thomas MC; Tsalamandris C; MacIsaac RJ; Jerums G
    Am J Kidney Dis; 2006 Oct; 48(4):537-45. PubMed ID: 16997049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of anemia in patients on hemodialysis.
    Aasebø W; Hartmann A; Jenssen T
    Hemodial Int; 2009 Jul; 13(3):335-9. PubMed ID: 19614760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An underappreciated problem in renal transplant recipients: anemia.
    Unal A; Sipahioglu MH; Akcakaya M; Tokgoz B; Sav T; Oymak O; Utas C
    Transplant Proc; 2008 Jun; 40(5):1399-403. PubMed ID: 18589116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
    McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
    Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
    Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
    J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
    Spiegel DM; Khan I; Krishnan M; Mayne TJ
    Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteinuria and hemoglobin levels in patients with primary glomerular disease.
    Mähr N; Neyer U; Prischl F; Kramar R; Mayer G; Kronenberg F; Lhotta K
    Am J Kidney Dis; 2005 Sep; 46(3):424-31. PubMed ID: 16129203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral ferrous sulfate does not increase preoperative hemoglobin in patients scheduled for hip or knee arthroplasty.
    Lachance K; Savoie M; Bernard M; Rochon S; Fafard J; Robitaille R; Vendittoli PA; Lévesque S; de Denus S
    Ann Pharmacother; 2011 Jun; 45(6):764-70. PubMed ID: 21666087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
    Beer TM; Tangen CM; Bland LB; Hussain M; Goldman BH; DeLoughery TG; Crawford ED;
    Cancer; 2006 Aug; 107(3):489-96. PubMed ID: 16804926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.